Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
BOBolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT)

NASDAQ Global Select · Currency in USD
$6.27 ▲ +2.08 (+49.64%)
At close: Oct 23, 4:00 PM ET. Market closed.
$6.55 ▲ +0.28 (+4.47%)
Pre-market: Oct 26, 8:11 AM ET

Summary

Previous Close
$4.19
Open
$6.98
Day's Range
$5.99 – $7.78
52 Week Range
$3.10 – $7.78
Volume
12,882,703
Avg. Volume
170,273
Market Cap
$12.08M
Beta (5Y Monthly)
1.01
PE Ratio (TTM)
--
EPS (TTM)
-$17.00
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
$0.02 (0.29%)
Ex-Dividend Date
Aug 29, 2014
1y Target Est
$4.00

Profile: Bolt Biotherapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
23
CEO
William Quinn

Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2).

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$3.69 · Revenue est. $426.25K
DateEst.Actual
Aug 11, 2026-$3.39-$4.57Miss
May 12, 2026-$2.85-$4.31Miss
Mar 12, 2026-$4.30-$3.84Beat
Nov 12, 2025-$5.07-$3.72Beat
Aug 14, 2025-$6.40-$4.46Beat
May 12, 2025-$6.80-$5.80Beat

Analyst view

Consensus price target
$4.00 ▼ -36.2%
Range $1.00 – $7.00
Rating: Hold
Buy 38% · Hold 63% · Sell 0%

Get free alerts on BOLT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.